Akero exec calls MASH accelerated approval guidance 'bizarre'
NEW YORK — Akero Therapeutics may not have adequate data for accelerated approval of its MASH drug, despite showing it may reverse cirrhosis in patients with severe liver disease. The problem, chief development officer Kitty Yale ...
NEW YORK — Akero Therapeutics may not have adequate data for accelerated approval of its MASH drug, despite showing it may reverse cirrhosis in patients with severe liver disease.
The problem, chief development officer Kitty Yale ...
